Sherbrooke Park Advisers LLC Biocryst Pharmaceuticals Inc Transaction History
Sherbrooke Park Advisers LLC
- $313 Billion
- Q4 2024
A detailed history of Sherbrooke Park Advisers LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Sherbrooke Park Advisers LLC holds 34,628 shares of BCRX stock, worth $271,137. This represents 0.08% of its overall portfolio holdings.
Number of Shares
34,628
Previous 27,494
25.95%
Holding current value
$271,137
Previous $209 Million
24.62%
% of portfolio
0.08%
Previous 0.05%
Shares
4 transactions
Others Institutions Holding BCRX
# of Institutions
277Shares Held
167MCall Options Held
728KPut Options Held
989K-
Vanguard Group Inc Valley Forge, PA21.9MShares$171 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$156 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.9MShares$92.9 Million1.3% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.09MShares$71.1 Million4.33% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY8.14MShares$63.8 Million1.52% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.46B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...